Implant Sciences Wins Parisian Airport Tender for 178 ETDs

WILMINGTON, Mass., July 21, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 178 of its QS-B220 desktop explosives trace detectors to all three major Parisian airports.

Over the past few months, Implant Sciences has won a series of tenders in France, as well as throughout the EU.  Following its two recent airport tender wins in France, the company's ETDs have been selected for deployment in over 95% of the French airports that serve more than 500,000 passengers annually.

"We have announced, combined with our contracts with the Union of French Airports (UAF) and Nice, a total of up to 507 QS-B220s sold to French airports over the last three months, and up to 783 altogether across the EU.  We believe that there is additional opportunity for our systems over the next several years in France, as well as across the rest of Europe, as the EU ETD regulations for airports with fewer than 500,000 passengers are set to be implemented after the major airports' installation of ETDs is complete," stated Dr. Darryl Jones, Vice President of Global Sales and Marketing for Implant Sciences. "The European market is as important to our expanding growth as the opportunity domestically is with the TSA, and we are pleased that our technology continues to receive favorable market acceptance."

"This is our third major contract in France. French airports have repeatedly chosen Implant Sciences over the competition because of our unparalleled non-rad expertise and superior product offering," added Richard Nelson, Implant Sciences' General Manager, EMEA. "We believe that our competitors simply cannot match our systems' performance and value.  When tested side by side, our low false alarm rate and system reliability demonstrate why the QS-B220 has been chosen by key aviation customers worldwide, including French airports, the majority of other ECAC-driven European aviation security buyers, and, of course, the TSA in the US."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation
Company Contact:
Robert Liscouski 
978-752-1700 x 116  

Photo - http://photos.prnewswire.com/prnh/20150721/238693

SOURCE Implant Sciences Corporation

Related Links

http://www.implantsciences.com